The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
FREE Daily Email Newsletter
PDL BioPharma Wants Arbitration in Royalty Dispute
June 11, 2013 6:17 pm | by The Associated Press | News | CommentsPDL BioPharma Inc. said Tuesday it wants take Roche's Genentech business to arbitration over a royalty payment dispute. PDL said Genentech has underpaid royalties since at least 2007, and it wants to have Genentech's books and records inspected to determine if...
Glaxo Fires Worker Over Misrepresented Study Data
June 11, 2013 5:22 pm | by The Associated Press | News | CommentsBritish drugmaker GlaxoSmithKline PLC says it dismissed one employee and a second has resigned in the wake of a scandal over misrepresented data in a research paper published in 2010. The company says its investigation of recent allegations of questionable data has established that some...
Roto-Mate™ Jib Crane Motorization Kits
June 11, 2013 11:34 am | Product Releases | CommentsNew higher capacity Roto-Mate™ jib crane motorization kits are employed to provide powered rotation to either existing or new wall-mounted or freestanding jib cranes with up to 10 ton loads.
Explosion Proof Approvals for AW210 WirelessHART Adapter
June 11, 2013 11:15 am | Product Releases | CommentsThe Sitrans AW210 WirelessHART adapter has received an explosion proof rating for intrinsically safe (Ex ia), nonincendive (Ex nA) and explosion proof (Ex d), offering increased safety in hazardous areas, along with the benefits of field level transparency and flexibility for process industries.
Fittings with Tube Ends
June 11, 2013 11:03 am | Product Releases | CommentsThe Mud Dauber series of fittings is now available with tube fitting ends, in Duolok ®, Unilok® and Griplok® designs. The fitting features a durable and replaceable screen element to prevent wasps and other insects from infiltrating and clogging open systems.
Questcor Will Pay at Least $135M for Novartis Drug
June 11, 2013 10:45 am | by The Associated Press | News | CommentsQuestcor Pharmaceuticals Inc. said Tuesday it will pay at least $135 million to buy an autoimmune and inflammatory disease drug made by Novartis AG, sending its shares surging in morning trading. Questcor said it will pay $60 million upfront for Synacthen and Synacthen Depot.
Software for Focused Screening
June 11, 2013 10:43 am | Product Releases | CommentsBiacore™ T200 Software v.2.0 enhances the capabilities of Biacore T200, offering researchers a flexible and powerful tool for efficient processing of molecular interaction data. Together, they facilitate label-free screening of low molecular weight compounds and low abundance proteins, giving detailed binding profiles on molecule-drug candidate mechanisms of action that ultimately assist in earlier lead selection and optimization.
Microporous Polymers
June 11, 2013 10:11 am | Product Releases | CommentsISP microporous polymers feature a three-dimensional pore structure that comes in a wide range of pore sizes from 1 to 195 microns and various widths and thicknesses, depending upon material.
Oil/Water Separators
June 11, 2013 9:44 am | Product Releases | CommentsSP oil/water separators, the versatile, high performance filtration unitsare designed to control liquid condensate containing oil and various other contaminants created by compressed air systems.
E-Cigarettes Catch Fire With Investors, Regulators
June 11, 2013 8:48 am | Videos | CommentsElectronic cigarettes are hot right now. While the cigarettes currently only account for 1% of the tobacco market their growth has doubled in size every year. But the young industry faces some very real hurdles from health and safety regulators.
Dynavax Falls as FDA Wants New Heplisav Study
June 11, 2013 8:28 am | News | CommentsDynavax said the FDA wants it to get safety data from more patients. The agency added that analyzing the drug for smaller groups of patients did not fully address its concerns. Those analyses could lead to a more limited approval of Heplisav, but according to Dynavax, the FDA said that might prevent patients who might benefit from the drug from getting treatment.
Questcor Names Former Shire CEO to Board
June 11, 2013 8:26 am | News | CommentsBiopharmaceutical company Questcor Pharmaceuticals Inc. said Monday that the recently retired CEO of Shire PLC, Angus C. Russell, has been added to its board. Russell was CEO of Shire, also a biopharmaceutical company, for five years. Before that, he was an executive at pharma companies ICI, Zeneca and AstraZeneca.
Aveo Says FDA Refuses to Approve Cancer Drug
June 11, 2013 8:21 am | News | CommentsAveo Oncology said Monday that the Food and Drug Administration has refused to approve its cancer drug tivozanib, saying the clinical trial data supporting the drug was not clear. The company said the FDA recommended it run a new clinical trial of tivozanib because it was not able to draw meaningful conclusions from a late-stage trial.
Feds Now Back Morning-After Pills for All Girls
June 11, 2013 8:13 am | by TOM HAYS,Associated Press | News | CommentsAfter setting off a storm of criticism from abortion rights groups upset that a Democratic president had sided with social conservatives, the Obama administration said it will comply with a judge's order to allow girls of any age to buy emergency contraception without prescriptions.
Forest Laboratories Appoints New Independent Director
June 11, 2013 8:10 am | News | CommentsForest Laboratories, Inc. today announced that, pursuant to an agreement with Carl C. Icahn and affiliated entities, its Board has appointed Vincent J. Intrieri as a new independent member of its Board of Directors. As part of the agreement, Mr. Icahn has agreed to vote the shares that he controls in support of Forest’s 11 director nominees and not run a proxy contest at the Company’s 2013 annual meeting.
